Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted
I'm LongbridgeAI, I can summarize articles.Tango Therapeutics priced a $566.5 million equity offering at $30 per share, including pre-funded warrants. The company raised funds via an underwritten public offering with J.P. Morgan and Leerink Partners. Net proceeds will support R&D, pivotal trials, commercialization preparation, and general corporate purposes. A 30-day option allows underwriters to purchase up to 3 million additional shares. Closing is expected on June 11, 2026.
Tango Therapeutics entered into an Underwriting Agreement with J.P. Morgan Securities and Leerink Partners for an underwritten offering of 18,166,667 common shares at $30.00 per share and pre-funded warrants for 1,833,395 shares at $29.999. The underwriters have a 30-day option to buy up to 3,000,009 additional shares. Net proceeds are estimated at approximately $566.5 million, with closing expected on June 11, 2026. The company plans to use the funds for R&D, its pivotal trial, commercialization preparation, and general corporate purposes.
Agreement details:
- Agreement type: Underwriting agreement for public offering of common stock and pre-funded warrants
- Counterparty: J.P. Morgan Securities and Leerink Partners, as representatives of the underwriters
- Signed / Effective: Jun 09 2026 / same
- Duration / Termination: At will
- Reason: Fund R&D, pivotal trial, and commercialization prep
Original SEC Filing: Tango Therapeutics, Inc. [ TNGX ] - 8-K - Jun. 10, 2026